Table 1 Characteristics of the study participants
Characteristics | CADS cohort | CABLE cohort | |
|---|---|---|---|
Total sample | CSF/plasma cohort | ||
n | 303 | 87 | 69 |
Age, years | 58.51 ± 16.59 | 69.60 ± 8.49 | 66.10 ± 8.02 |
Gender, female (%) | 122 (40.26) | 50 (57.47) | 32 (46.38) |
Education level, years | 11.10 ± 3.53 | 7.38 ± 4.80 | 8.45 ± 4.14 |
APOE ε4 carriers, No. (%) | 54 (17.82) | 15 (17.24) | 11 (15.94) |
Hypertension, No. (%) | 75 (24.75) | 33 (37.93) | 35 (50.72) |
T2DM, No. (%) | 36 (11.88) | 19 (21.84) | 11 (15.94) |
Hyperlipidemia, No. (%) | 6 (1.98) | 3 (3.45) | 2 (2.90) |
CHD, No. (%) | 13 (4.29) | 7 (8.05) | 14 (20.29) |
History of stroke, No. (%) | 5 (1.65) | 4 (4.60) | 2 (2.90) |
Current smokers, No. (%) | 75 (24.75) | 16 (18.39) | 15 (21.74) |
CSF sPDGFRβ, pg/mL | 556.52 ± 287.93 | 713.37 ± 285.61 | 639.39 ± 221.52 |
CSF Aβ40, pg/mL | 11,138.83 ± 4575.39 | 12,253.49 ± 4481.98 | 6808.56 ± 3161.62 |
CSF Aβ42, pg/mL | 1314.64 ± 513.43 | 1329.62 ± 721.32 | 187.24 ± 115.29 |
CSF T-tau, pg/mL | 182.45 ± 93.06 | 203.17 ± 67.50 | 202.83 ± 124.52 |
CSF P-tau181, pg/mL | 43.55 ± 18.46 | 49.71 ± 20.13 | 41.12 ± 14.31 |
CSF/plasma Aβ40 | NA | 45.88 ± 20.37 | NA |
CSF/plasma Aβ42 | NA | 61.01 ± 31.94 | NA |
CSF/plasma t-tau | NA | 30.48 ± 16.07 | NA |